Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis

SGLT-2 inhibitors resulted in a 0.11% greater reduction in hemoglobin A1c compared to DPP-4 inhibitors at ≥52 weeks.

• SGLT-2 inhibitors resulted in significant weight loss of -2.31 kg at ≤26 weeks and -2.45 kg at ≥52 weeks compared to DPP-4 inhibitors.
• No significant difference in hemoglobin A1c reduction between SGLT-2 and DPP-4 inhibitors was observed at ≤26 weeks.
• Patients on SGLT-2 inhibitors experienced significantly more genital infections compared to those on DPP-4 inhibitors.
• Higher doses of SGLT-2 inhibitors were associated with greater efficacy in reducing hemoglobin A1c at ≥52 weeks.
• DPP-4 inhibitors may be more effective for patients with a baseline hemoglobin A1c <8.5%, while SGLT-2 inhibitors may be preferred for those with ≥8.5%.

AI simplified